[8-K] SouthState Corporation Reports Material Event
Fennec Pharmaceuticals Inc. (FENC) 鈥� Form 144 filing discloses that insider Rostislav Raykov has notified the SEC of his intent to sell up to 10,000 common shares through Morgan Stanley Smith Barney on or after 03 July 2025. At the 30 June 2025 closing price used in the filing, the aggregate market value of the proposed sale is $86,102, equivalent to roughly 0.036 % of the 27.6 million shares outstanding.
The shares stem from recently vested restricted-stock grants acquired on 16 May 2025 (7,570 sh) and 30 June 2025 (2,430 sh). The filing also details that Raykov has already disposed of 46,667 shares between 4 April and 5 June 2025 for total gross proceeds of approximately $295,398.
Rule 144 notices do not guarantee execution, but repeated insider sales within a short window can influence market sentiment. Nevertheless, the cumulative volume over the past quarter plus the planned sale (鈮�56,667 shares) remains below 0.21 % of outstanding shares, suggesting limited dilution or supply pressure.
Fennec Pharmaceuticals Inc. (FENC) 鈥� Comunicazione Form 144 rivela che l'insider Rostislav Raykov ha notificato alla SEC la sua intenzione di vendere fino a 10.000 azioni ordinarie tramite Morgan Stanley Smith Barney a partire dal 3 luglio 2025. Al prezzo di chiusura del 30 giugno 2025 utilizzato nella comunicazione, il valore di mercato complessivo della vendita proposta 猫 di 86.102 $, pari a circa il 0,036% delle 27,6 milioni di azioni in circolazione.
Le azioni provengono da assegnazioni di azioni vincolate recentemente maturate, acquisite il 16 maggio 2025 (7.570 azioni) e il 30 giugno 2025 (2.430 azioni). La comunicazione specifica inoltre che Raykov ha gi脿 venduto 46.667 azioni tra il 4 aprile e il 5 giugno 2025, per un ricavo lordo totale di circa 295.398 $.
Le notifiche secondo la Regola 144 non garantiscono l鈥檈ffettiva esecuzione della vendita, ma vendite ripetute da parte degli insider in un breve intervallo possono influenzare il sentiment di mercato. Tuttavia, il volume cumulativo nell鈥檜ltimo trimestre pi霉 la vendita pianificata (circa 56.667 azioni) rimane inferiore al 0,21% delle azioni in circolazione, suggerendo un impatto limitato su diluizione o pressione di offerta.
Fennec Pharmaceuticals Inc. (FENC) 鈥� Presentaci贸n del Formulario 144 revela que el insider Rostislav Raykov ha notificado a la SEC su intenci贸n de vender hasta 10,000 acciones comunes a trav茅s de Morgan Stanley Smith Barney a partir del 3 de julio de 2025. Al precio de cierre del 30 de junio de 2025 usado en la presentaci贸n, el valor de mercado total de la venta propuesta es de $86,102, equivalente aproximadamente al 0.036% de las 27.6 millones de acciones en circulaci贸n.
Las acciones provienen de concesiones de acciones restringidas recientemente adquiridas, fechadas el 16 de mayo de 2025 (7,570 acciones) y el 30 de junio de 2025 (2,430 acciones). La presentaci贸n tambi茅n detalla que Raykov ya ha vendido 46,667 acciones entre el 4 de abril y el 5 de junio de 2025, obteniendo ingresos brutos totales de aproximadamente $295,398.
Las notificaciones bajo la Regla 144 no garantizan la ejecuci贸n, pero ventas repetidas por parte de insiders en un corto periodo pueden influir en el sentimiento del mercado. No obstante, el volumen acumulado en el 煤ltimo trimestre m谩s la venta planeada (鈮�56,667 acciones) sigue siendo inferior al 0.21% de las acciones en circulaci贸n, lo que sugiere una diluci贸n o presi贸n de oferta limitada.
Fennec Pharmaceuticals Inc. (FENC) 鈥� Form 144 鞝滌稖鞐� 霐半ゴ氅� 雮措秬鞛� Rostislav Raykov臧� 2025雲� 7鞗� 3鞚� 鞚错泟 氇贝 鞀ろ儬毽� 鞀る鞀� 氚旊媹毳� 韱淀暣 斓滊寑 10,000 氤错喌欤�毳� 毵る弰頃� 鞚橃偓毳� SEC鞐� 韱奠頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 靷毄霅� 2025雲� 6鞗� 30鞚� 膦呹皜 旮办鞙茧, 鞝滌晥霅� 毵る弰鞚� 齑� 鞁滌灔 臧�旃橂姅 86,102 雼煬搿�, 鞚措姅 鞎� 2,760毵� 欤� 欷� 0.036%鞐� 頃措嫻頃╇媹雼�.
鞚� 欤检嫕霌れ潃 斓滉芳鞐� 旆摑頃� 鞝滍暅 欤检嫕鞙茧, 2025雲� 5鞗� 16鞚� (7,570欤�)鞕赌 2025雲� 6鞗� 30鞚� (2,430欤�)鞐� 臧侁皝 旆摑霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 Raykov臧� 2025雲� 4鞗� 4鞚茧秬韯� 6鞗� 5鞚� 靷澊鞐� 鞚措 46,667欤�毳� 毵る弰頃橃棳 齑� 鞎� 295,398 雼煬鞚� 齑� 靾橃澋鞚� 鞓牳雼る姅 雮挫毄霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
攴滌箼 144 韱奠電� 毵る弰 鞁ろ枆鞚� 氤挫灔頃橃 鞎婌毵�, 雼赴臧� 雮� 氚橂车霅橂姅 雮措秬鞛� 毵る弰電� 鞁滌灔 鞁Μ鞐� 鞓來枼鞚� 欷� 靾� 鞛堨姷雼堧嫟. 攴鸽熂鞐愲弰 攵堦惮頃橁碃, 歆�雮� 攵勱赴 雸勳爜 毵る弰霟夑臣 瓿勴殟霅� 毵る弰霟�(鞎� 56,667欤�)鞚� 鞝勳泊 氚滍枆 欤检嫕鞚� 0.21% 氙鸽鞙茧, 頋劃 須臣雮� 瓿店笁 鞎曤牓鞚� 鞝滍暅鞝侅澕 瓴冹溂搿� 氤挫瀰雼堧嫟.
Fennec Pharmaceuticals Inc. (FENC) 鈥� D茅p么t du formulaire 144 r茅v猫le que l鈥檌niti茅 Rostislav Raykov a inform茅 la SEC de son intention de vendre jusqu鈥櫭� 10 000 actions ordinaires via Morgan Stanley Smith Barney 脿 partir du 3 juillet 2025. Au cours de cl么ture du 30 juin 2025 utilis茅 pour le d茅p么t, la valeur totale de la vente propos茅e est de 86 102 $, ce qui repr茅sente environ 0,036 % des 27,6 millions d鈥檃ctions en circulation.
Les actions proviennent d鈥檃ttributions d鈥檃ctions restreintes r茅cemment acquises, dat茅es du 16 mai 2025 (7 570 actions) et du 30 juin 2025 (2 430 actions). Le d茅p么t pr茅cise 茅galement que Raykov a d茅j脿 c茅d茅 46 667 actions entre le 4 avril et le 5 juin 2025, pour un produit brut total d鈥檈nviron 295 398 $.
Les notifications selon la r猫gle 144 ne garantissent pas l鈥檈x茅cution, mais des ventes r茅p茅t茅es d鈥檌niti茅s sur une courte p茅riode peuvent influencer le sentiment du march茅. N茅anmoins, le volume cumul茅 du dernier trimestre plus la vente pr茅vue (environ 56 667 actions) reste inf茅rieur 脿 0,21 % des actions en circulation, ce qui sugg猫re une dilution ou une pression d鈥檕ffre limit茅e.
Fennec Pharmaceuticals Inc. (FENC) 鈥� Form 144 Einreichung gibt bekannt, dass Insider Rostislav Raykov der SEC seine Absicht mitgeteilt hat, bis zu 10.000 Stammaktien 眉ber Morgan Stanley Smith Barney am oder nach dem 3. Juli 2025 zu verkaufen. Basierend auf dem Schlusskurs vom 30. Juni 2025, der in der Einreichung verwendet wurde, betr盲gt der Gesamtmarktwert des geplanten Verkaufs 86.102 $, was etwa 0,036 % der 27,6 Millionen ausstehenden Aktien entspricht.
Die Aktien stammen aus k眉rzlich f盲lligen Restricted-Stock-Zuweisungen vom 16. Mai 2025 (7.570 Aktien) und 30. Juni 2025 (2.430 Aktien). Die Einreichung gibt au脽erdem an, dass Raykov bereits zwischen dem 4. April und 5. Juni 2025 46.667 Aktien ver盲u脽ert hat und dabei Bruttoerl枚se von etwa 295.398 $ erzielte.
Rule 144-Mitteilungen garantieren keine Ausf眉hrung, aber wiederholte Insiderverk盲ufe in kurzer Zeit k枚nnen die Marktstimmung beeinflussen. Dennoch bleibt das kumulierte Volumen im letzten Quartal zuz眉glich des geplanten Verkaufs (ca. 56.667 Aktien) unter 0,21 % der ausstehenden Aktien, was auf eine begrenzte Verw盲sserung oder Angebotsdruck hindeutet.
- None.
- Continued insider selling by the same executive within a three-month span may raise minor sentiment concerns despite small relative volume.
Insights
TL;DR 鈥� Small insider sale; signal slightly negative but immaterial to float.
The proposed 10 k-share sale represents a de-minimis 0.04 % of shares outstanding. While continued selling by the same insider may be read as waning confidence, the notional value is modest ($86k) and follows recent option/RSU vesting. From a liquidity standpoint, the NASDAQ daily volume averages far above this level, so price impact should be minimal. I view the disclosure as neutral-to-slightly negative for sentiment, with no change to fundamentals.
TL;DR 鈥� Patterned insider disposals warrant monitoring for governance optics.
Raykov has filed multiple Form 144s and executed sales over three consecutive months, signalling a structured liquidation program. Although Rule 144 compliance and 10b5-1 safeguards are noted, investors often scrutinise repeat sales by senior officers for alignment concerns. Yet, aggregate disposals remain far below thresholds that typically trigger governance red flags. I deem the filing not materially impactful but recommend tracking future filings to confirm whether the pattern escalates.
Fennec Pharmaceuticals Inc. (FENC) 鈥� Comunicazione Form 144 rivela che l'insider Rostislav Raykov ha notificato alla SEC la sua intenzione di vendere fino a 10.000 azioni ordinarie tramite Morgan Stanley Smith Barney a partire dal 3 luglio 2025. Al prezzo di chiusura del 30 giugno 2025 utilizzato nella comunicazione, il valore di mercato complessivo della vendita proposta 猫 di 86.102 $, pari a circa il 0,036% delle 27,6 milioni di azioni in circolazione.
Le azioni provengono da assegnazioni di azioni vincolate recentemente maturate, acquisite il 16 maggio 2025 (7.570 azioni) e il 30 giugno 2025 (2.430 azioni). La comunicazione specifica inoltre che Raykov ha gi脿 venduto 46.667 azioni tra il 4 aprile e il 5 giugno 2025, per un ricavo lordo totale di circa 295.398 $.
Le notifiche secondo la Regola 144 non garantiscono l鈥檈ffettiva esecuzione della vendita, ma vendite ripetute da parte degli insider in un breve intervallo possono influenzare il sentiment di mercato. Tuttavia, il volume cumulativo nell鈥檜ltimo trimestre pi霉 la vendita pianificata (circa 56.667 azioni) rimane inferiore al 0,21% delle azioni in circolazione, suggerendo un impatto limitato su diluizione o pressione di offerta.
Fennec Pharmaceuticals Inc. (FENC) 鈥� Presentaci贸n del Formulario 144 revela que el insider Rostislav Raykov ha notificado a la SEC su intenci贸n de vender hasta 10,000 acciones comunes a trav茅s de Morgan Stanley Smith Barney a partir del 3 de julio de 2025. Al precio de cierre del 30 de junio de 2025 usado en la presentaci贸n, el valor de mercado total de la venta propuesta es de $86,102, equivalente aproximadamente al 0.036% de las 27.6 millones de acciones en circulaci贸n.
Las acciones provienen de concesiones de acciones restringidas recientemente adquiridas, fechadas el 16 de mayo de 2025 (7,570 acciones) y el 30 de junio de 2025 (2,430 acciones). La presentaci贸n tambi茅n detalla que Raykov ya ha vendido 46,667 acciones entre el 4 de abril y el 5 de junio de 2025, obteniendo ingresos brutos totales de aproximadamente $295,398.
Las notificaciones bajo la Regla 144 no garantizan la ejecuci贸n, pero ventas repetidas por parte de insiders en un corto periodo pueden influir en el sentimiento del mercado. No obstante, el volumen acumulado en el 煤ltimo trimestre m谩s la venta planeada (鈮�56,667 acciones) sigue siendo inferior al 0.21% de las acciones en circulaci贸n, lo que sugiere una diluci贸n o presi贸n de oferta limitada.
Fennec Pharmaceuticals Inc. (FENC) 鈥� Form 144 鞝滌稖鞐� 霐半ゴ氅� 雮措秬鞛� Rostislav Raykov臧� 2025雲� 7鞗� 3鞚� 鞚错泟 氇贝 鞀ろ儬毽� 鞀る鞀� 氚旊媹毳� 韱淀暣 斓滊寑 10,000 氤错喌欤�毳� 毵る弰頃� 鞚橃偓毳� SEC鞐� 韱奠頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 靷毄霅� 2025雲� 6鞗� 30鞚� 膦呹皜 旮办鞙茧, 鞝滌晥霅� 毵る弰鞚� 齑� 鞁滌灔 臧�旃橂姅 86,102 雼煬搿�, 鞚措姅 鞎� 2,760毵� 欤� 欷� 0.036%鞐� 頃措嫻頃╇媹雼�.
鞚� 欤检嫕霌れ潃 斓滉芳鞐� 旆摑頃� 鞝滍暅 欤检嫕鞙茧, 2025雲� 5鞗� 16鞚� (7,570欤�)鞕赌 2025雲� 6鞗� 30鞚� (2,430欤�)鞐� 臧侁皝 旆摑霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 Raykov臧� 2025雲� 4鞗� 4鞚茧秬韯� 6鞗� 5鞚� 靷澊鞐� 鞚措 46,667欤�毳� 毵る弰頃橃棳 齑� 鞎� 295,398 雼煬鞚� 齑� 靾橃澋鞚� 鞓牳雼る姅 雮挫毄霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
攴滌箼 144 韱奠電� 毵る弰 鞁ろ枆鞚� 氤挫灔頃橃 鞎婌毵�, 雼赴臧� 雮� 氚橂车霅橂姅 雮措秬鞛� 毵る弰電� 鞁滌灔 鞁Μ鞐� 鞓來枼鞚� 欷� 靾� 鞛堨姷雼堧嫟. 攴鸽熂鞐愲弰 攵堦惮頃橁碃, 歆�雮� 攵勱赴 雸勳爜 毵る弰霟夑臣 瓿勴殟霅� 毵る弰霟�(鞎� 56,667欤�)鞚� 鞝勳泊 氚滍枆 欤检嫕鞚� 0.21% 氙鸽鞙茧, 頋劃 須臣雮� 瓿店笁 鞎曤牓鞚� 鞝滍暅鞝侅澕 瓴冹溂搿� 氤挫瀰雼堧嫟.
Fennec Pharmaceuticals Inc. (FENC) 鈥� D茅p么t du formulaire 144 r茅v猫le que l鈥檌niti茅 Rostislav Raykov a inform茅 la SEC de son intention de vendre jusqu鈥櫭� 10 000 actions ordinaires via Morgan Stanley Smith Barney 脿 partir du 3 juillet 2025. Au cours de cl么ture du 30 juin 2025 utilis茅 pour le d茅p么t, la valeur totale de la vente propos茅e est de 86 102 $, ce qui repr茅sente environ 0,036 % des 27,6 millions d鈥檃ctions en circulation.
Les actions proviennent d鈥檃ttributions d鈥檃ctions restreintes r茅cemment acquises, dat茅es du 16 mai 2025 (7 570 actions) et du 30 juin 2025 (2 430 actions). Le d茅p么t pr茅cise 茅galement que Raykov a d茅j脿 c茅d茅 46 667 actions entre le 4 avril et le 5 juin 2025, pour un produit brut total d鈥檈nviron 295 398 $.
Les notifications selon la r猫gle 144 ne garantissent pas l鈥檈x茅cution, mais des ventes r茅p茅t茅es d鈥檌niti茅s sur une courte p茅riode peuvent influencer le sentiment du march茅. N茅anmoins, le volume cumul茅 du dernier trimestre plus la vente pr茅vue (environ 56 667 actions) reste inf茅rieur 脿 0,21 % des actions en circulation, ce qui sugg猫re une dilution ou une pression d鈥檕ffre limit茅e.
Fennec Pharmaceuticals Inc. (FENC) 鈥� Form 144 Einreichung gibt bekannt, dass Insider Rostislav Raykov der SEC seine Absicht mitgeteilt hat, bis zu 10.000 Stammaktien 眉ber Morgan Stanley Smith Barney am oder nach dem 3. Juli 2025 zu verkaufen. Basierend auf dem Schlusskurs vom 30. Juni 2025, der in der Einreichung verwendet wurde, betr盲gt der Gesamtmarktwert des geplanten Verkaufs 86.102 $, was etwa 0,036 % der 27,6 Millionen ausstehenden Aktien entspricht.
Die Aktien stammen aus k眉rzlich f盲lligen Restricted-Stock-Zuweisungen vom 16. Mai 2025 (7.570 Aktien) und 30. Juni 2025 (2.430 Aktien). Die Einreichung gibt au脽erdem an, dass Raykov bereits zwischen dem 4. April und 5. Juni 2025 46.667 Aktien ver盲u脽ert hat und dabei Bruttoerl枚se von etwa 295.398 $ erzielte.
Rule 144-Mitteilungen garantieren keine Ausf眉hrung, aber wiederholte Insiderverk盲ufe in kurzer Zeit k枚nnen die Marktstimmung beeinflussen. Dennoch bleibt das kumulierte Volumen im letzten Quartal zuz眉glich des geplanten Verkaufs (ca. 56.667 Aktien) unter 0,21 % der ausstehenden Aktien, was auf eine begrenzte Verw盲sserung oder Angebotsdruck hindeutet.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 | Regulation FD Disclosures. |
SouthState Corporation to announce quarterly earnings results on Thursday, July 24, 2025
Winter Haven, FL. – July 3, 2025 – SouthState Corporation (NYSE: SSB) (“SouthState”) announced today that it will release second quarter 2025 earnings results on Thursday, July 24, 2025, after the market closes. Upon release, investors may access a copy of SouthState’s earnings results at the Company’s website at www.SouthStateBank.com under Investor Relations, News, News & Market Data section.
SouthState will host a conference call on Friday, July 25, 2025 at 9:00 a.m. (ET) to discuss its second quarter 2025 results. Investors may call in (toll free) by dialing (888) 350-3899 within the US and (646) 960-0343 for all other locations (host: Will Matthews, CFO). The numbers for international participants are listed at https://events.q4irportal.com/custom/access/2324/. The conference ID number is 4200408. Participants may also pre-register for the conference by navigating to https://events.q4inc.com/attendee/102549480. Access detail will be provided via email upon completion of registration.
Alternatively, individuals may listen to the live webcast of the presentation by visiting the link at SouthState’s website at www.SouthStateBank.com. An audio replay of the live webcast is expected to be available by the evening of Friday, July 25, 2025 through the Investor Relations section of www.SouthStateBank.com.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits. | ||
Exhibit No. | Description of Exhibit | |
99.1 | Press release dated July 3, 2025 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SOUTHSTATE CORPORATION | ||
(Registrant) | ||
By: | /s/ William E. Matthews, V | |
Dated: July 3, 2025
3
Source:
FAQ
How many FENC shares is the insider planning to sell under this Form 144?
What is the aggregate market value of the proposed FENC share sale?
When is the anticipated sale date for the FENC shares?
How many FENC shares has the insider already sold in the past three months?
What percentage of Fennec Pharmaceuticals鈥� shares outstanding does the planned sale represent?
Which brokerage firm is handling the planned sale of FENC shares?
